Arbutus Biopharma Corporation ABUS Number of wholly-owed subsidiaries

Other financials

Revenue$179.1M+10,055%

Operating income$168.9M+757%

Net income$169.7M+792%

EPS (diluted)$0.87+769%

Cash & equivalents$23.7M-36.1%

Total debt$631.0K-46.9%

Total equity$260.2M+229%

Total assets$277.2M+137%

Operating cash flow-$8.1M+39.4%

CapEx--100%

Free cash flow-$4.7M+55.0%

Market cap$871.14M+32.6%

Enterprise value$848.07M+36.6%

P/E5.4×—

P/S4.6×-98.0×

Operating margin81.7%+42.1pp

Net margin84%+43.4pp

FCF margin-281.5%-119pp

Return on equity94.7%+65.1pp

Debt / equity0×0.0×

Current ratio54.3×+48.3×

Reported directly by Arbutus Biopharma Corporation in its filing.

Tagged under the XBRL concept abus:WhollyOwnedSubsidiariesIncludedinFinancialStatements.

The official record: Arbutus Biopharma Corporation’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and see it in context, right in your chat.

What is Arbutus Biopharma Corporation's number of wholly-owed subsidiaries?: Arbutus Biopharma Corporation (ABUS) reported number of wholly-owed subsidiaries of 1 in Q1 2026.
How has Arbutus Biopharma Corporation's number of wholly-owed subsidiaries changed year-over-year?: Arbutus Biopharma Corporation's number of wholly-owed subsidiaries decreased by 0.0% year-over-year, from 1 to 1.